(Reuters) – The adverse events that led to a pause in trials evaluating AstraZeneca Plc’s COVID-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted https://covid19vaccinetrial.co.uk/files/cov002pisages18-55yearsv11011sept2020pdf online by the Oxford University.
(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)
